310 related articles for article (PubMed ID: 33144118)
21. THE ANALYSIS OF LGI1 GENE EPIGENETIC ALTERATIONS BY MEANS OF POSTTRANSLATIONAL H3 HISTONE MODIFICATIONS IN MALIGNANT GLIOMAS.
Semenova EV; Volnitsky AV; Filatov MV
Tsitologiia; 2016; 58(5):335-9. PubMed ID: 30188624
[TBL] [Abstract][Full Text] [Related]
22. Advances in epigenetic glioblastoma therapy.
Lee DH; Ryu HW; Won HR; Kwon SH
Oncotarget; 2017 Mar; 8(11):18577-18589. PubMed ID: 28099914
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors.
Singh MM; Manton CA; Bhat KP; Tsai WW; Aldape K; Barton MC; Chandra J
Neuro Oncol; 2011 Aug; 13(8):894-903. PubMed ID: 21653597
[TBL] [Abstract][Full Text] [Related]
24. Exploring the Multi-Faceted Role of Sirtuins in Glioblastoma Pathogenesis and Targeting Options.
Kunadis E; Piperi C
Int J Mol Sci; 2022 Oct; 23(21):. PubMed ID: 36361680
[TBL] [Abstract][Full Text] [Related]
25. Current and future therapeutic strategies for high-grade gliomas leveraging the interplay between epigenetic regulators and kinase signaling networks.
Stitzlein LM; Adams JT; Stitzlein EN; Dudley RW; Chandra J
J Exp Clin Cancer Res; 2024 Jan; 43(1):12. PubMed ID: 38183103
[TBL] [Abstract][Full Text] [Related]
26. Emerging role of linker histone variant H1x as a biomarker with prognostic value in astrocytic gliomas. A multivariate analysis including trimethylation of H3K9 and H4K20.
Sepsa A; Levidou G; Gargalionis A; Adamopoulos C; Spyropoulou A; Dalagiorgou G; Thymara I; Boviatsis E; Themistocleous MS; Petraki K; Vrettakos G; Samaras V; Zisakis A; Patsouris E; Piperi C; Korkolopoulou P
PLoS One; 2015; 10(1):e0115101. PubMed ID: 25602259
[TBL] [Abstract][Full Text] [Related]
27. No Significant Cytotoxic Effect of the EZH2 Inhibitor Tazemetostat (EPZ-6438) on Pediatric Glioma Cells with Wildtype Histone 3 or Mutated Histone 3.3.
Wiese M; Schill F; Sturm D; Pfister S; Hulleman E; Johnsen SA; Kramm CM
Klin Padiatr; 2016 Apr; 228(3):113-7. PubMed ID: 27135271
[TBL] [Abstract][Full Text] [Related]
28. An Alternatively Spliced Sirtuin 2 Isoform 5 Inhibits Hepatitis B Virus Replication from cccDNA by Repressing Epigenetic Modifications Made by Histone Lysine Methyltransferases.
Piracha ZZ; Saeed U; Kim J; Kwon H; Chwae YJ; Lee HW; Lim JH; Park S; Shin HJ; Kim K
J Virol; 2020 Jul; 94(16):. PubMed ID: 32493816
[TBL] [Abstract][Full Text] [Related]
29. The Multifaceted Glioblastoma: From Genomic Alterations to Metabolic Adaptations.
Quinones A; Le A
Adv Exp Med Biol; 2021; 1311():59-76. PubMed ID: 34014534
[TBL] [Abstract][Full Text] [Related]
30. Emerging trends in post-translational modification: Shedding light on Glioblastoma multiforme.
Kumari S; Gupta R; Ambasta RK; Kumar P
Biochim Biophys Acta Rev Cancer; 2023 Nov; 1878(6):188999. PubMed ID: 37858622
[TBL] [Abstract][Full Text] [Related]
31. The "Epigenetic Code Replication Machinery", ECREM: a promising drugable target of the epigenetic cell memory.
Bronner C; Chataigneau T; Schini-Kerth VB; Landry Y
Curr Med Chem; 2007; 14(25):2629-41. PubMed ID: 17979715
[TBL] [Abstract][Full Text] [Related]
32. Deregulation of histone-modifying enzymes and chromatin structure modifiers contributes to glioma development.
Maleszewska M; Kaminska B
Future Oncol; 2015 Sep; 11(18):2587-601. PubMed ID: 26289459
[TBL] [Abstract][Full Text] [Related]
33. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy.
Ramaiah MJ; Tangutur AD; Manyam RR
Life Sci; 2021 Jul; 277():119504. PubMed ID: 33872660
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced modifications and modulations of microRNAs and long non-coding RNAs for future therapy against Glioblastoma Multiforme.
Janaki Ramaiah M; Divyapriya K; Kartik Kumar S; Rajesh YBRD
Gene; 2020 Jan; 723():144126. PubMed ID: 31589963
[TBL] [Abstract][Full Text] [Related]
35. Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes.
Damodaran S; Damaschke N; Gawdzik J; Yang B; Shi C; Allen GO; Huang W; Denu J; Jarrard D
BMC Cancer; 2017 Dec; 17(1):874. PubMed ID: 29262808
[TBL] [Abstract][Full Text] [Related]
36. Histone-modifying enzymes: encrypting an enigmatic epigenetic code.
Couture JF; Trievel RC
Curr Opin Struct Biol; 2006 Dec; 16(6):753-60. PubMed ID: 17070031
[TBL] [Abstract][Full Text] [Related]
37. Histone modification therapy of cancer.
Biancotto C; Frigè G; Minucci S
Adv Genet; 2010; 70():341-86. PubMed ID: 20920755
[TBL] [Abstract][Full Text] [Related]
38. A lesson learned from the H3.3K27M mutation found in pediatric glioma: a new approach to the study of the function of histone modifications in vivo?
Chan KM; Han J; Fang D; Gan H; Zhang Z
Cell Cycle; 2013 Aug; 12(16):2546-52. PubMed ID: 23907119
[TBL] [Abstract][Full Text] [Related]
39. EHMT2/G9a as an Epigenetic Target in Pediatric and Adult Brain Tumors.
Souza BK; Freire NH; Jaeger M; de Farias CB; Brunetto AL; Brunetto AT; Roesler R
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681949
[TBL] [Abstract][Full Text] [Related]
40. PGE2 induces interleukin-8 derepression in human astrocytoma through coordinated DNA demethylation and histone hyperacetylation.
Venza I; Visalli M; Fortunato C; Ruggeri M; Ratone S; Caffo M; Caruso G; Alafaci C; Tomasello F; Teti D; Venza M
Epigenetics; 2012 Nov; 7(11):1315-30. PubMed ID: 23051921
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
